By Fineline Cube 
China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its P134 cell injection. The study will evaluate the autologous chimeric antigen receptor (CAR-T) therapy in patients with recurrent glioblastoma, marking a significant step forward in the development of novel treatments for this aggressive form of brain cancer.
P134: Innovative CAR-T Product
P134, co-developed by China’s Beijing Neurosurgical Institute, is a unique CAR-T product targeting CD44 and/or CD133. It specifically recognizes and binds to highly expressed antigen targets that are mutually exclusive in primary and recurrent glioblastoma (GBM). This mechanism efficiently activates and prolongs the lifespan of T cells, enhancing their ability to kill tumor cells. The therapy addresses a critical unmet need, as no similar product is currently approved for recurrent glioblastoma anywhere in the world.-Fineline Info & Tech